C21 Investments Inc.

C21 Investments Inc. operates as a comprehensive enterprise within the cannabis sector, handling the cultivation, processing, distribution, and retail of consumer goods derived from cannabis and hemp throughout the United States. Its diverse product lineup includes both pre-packaged and bulk cannabis flower, vaporizer cartridges, concentrated extracts, edible products, pre-rolled joints, liquid tinctures, and topical applications. In addition, the company provides payroll administration and employee benefits solutions. Originally incorporated in 1987, the firm rebranded to C21 Investments Inc. in November 2017, having previously operated under the name Curlew Lake Resources Inc. Its primary corporate headquarters are situated in Vancouver, Canada.

C21 Investments Inc. trades as CXXI.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $33.27M of revenue and -$3.44M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

C21 Investments Inc. can be compared against peers such as Cannabix Technologies Inc., The Cannabist Company Holdings Inc., Decibel Cannabis Company Inc., 1CM Inc., iAnthus Capital Holdings, Inc., InnoCan Pharma Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $49.52M, beta of 1.85, and return on equity of -12.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CXXI.CN currently shows total debt of $10.95M and beta of 1.85. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.cxxi.ca

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.